Literature DB >> 6180128

The role of liver in the catabolism of human alpha- and beta-interferon.

V Bocci, A Pacini, L Bandinelli, G P Pessina, M Muscettola, L Paulesu.   

Abstract

The susceptibility of human leukocyte (alpha), fibroblast (beta) and recombinant alpha-2-interferons to clearance by the isolated and perfused rabbit liver has been evaluated. Human leukocyte and recombinant alpha-2-interferons were stable and their initial levels were maintained in the perfusate even if they had been treated with neuraminidase, thus suggesting that alpha-interferons have no exposed sugars recognizable by hepatic binding proteins. On the other hand, native, and particularly desialylated human beta-interferon, underwent marked hepatic uptake confirming the importance of the liver as a catabolic site for glycosylated interferons.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6180128     DOI: 10.1099/0022-1317-60-2-397

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects.

Authors:  Samir K Gupta; Paul Glue; Sheila Jacobs; Donna Belle; Melton Affrime
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Pharmacokinetics of recombinant interferon alpha-C.

Authors:  O Merimsky; M Rubinstein; D Fischer; A Danon; S Chaitchik
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma.

Authors:  V Bocci; M Muscettola; G Grasso; Z Magyar; A Naldini; G Szabo
Journal:  Experientia       Date:  1986-04-15

Review 5.  Catabolism of interferons.

Authors:  V Bocci
Journal:  Surv Immunol Res       Date:  1982

Review 6.  Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Authors:  A Bayas; P Rieckmann
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.